| 林显营，莫秀丽，方柏.美托洛尔联合左西孟旦对慢性心力衰竭患者血清学指标及心肌纤维化标志物的影响[J].中国医药科学,2022,(4):77-79 基金项目: |
| 美托洛尔联合左西孟旦对慢性心力衰竭患者血清学指标及心肌纤维化标志物的影响 |
| Effects of metoprolol combined with levosimendan on serological indexes and myocardial fibrosis markers in patients with chronic heart failure |
| |
| DOI： |
| 中文关键词: 慢性心力衰竭；美托洛尔；左西孟旦；心肌纤维化 |
| 英文关键词:Chronic heart failure; Metoprolol; Levosimendan; Myocardial fibrosis |
| 作者 | 单位 | | 林显营，莫秀丽，方柏 | 广东省廉江市人民医院心内科，广东廉江 524400 |
|
| 摘要点击次数: 760 |
| 全文下载次数: 2444 |
| 中文摘要: |
| [摘要] 目的 探讨美托洛尔联合左西孟旦在慢性心力衰竭（CHF）患者中的应用效果。 方法 选取2019年9月至2020年9月于广东省廉江市人民医院就诊的78例CHF患者，按照随机数字表法分成两组，每组各39例。对照组予以美托洛尔，观察组加用左西孟旦，连续用药14 d。比较两组临床疗效、血清学指标、心肌纤维化标志物水平、不良反应。 结果 观察组治疗总有效率为94.87%，高于对照组的76.92%，差异有统计学意义（P < 0.05）；治疗前，两组患者心肌肌钙蛋白（cTnT）、N-末端B型利钠肽前体（NT-proBNP）、金属蛋白酶9（MMP-9）、透明质酸（HA）、层粘连蛋白（LN）、结缔组织生长因子（CTGF）、Ⅲ型前胶原氨基末端肽（PⅢNP）水平比较，差异无统计学意义（P > 0.05）；治疗后，观察组cTnT、NT-proBNP、MMP-9和HA、LN、CTGF、PⅢNP水平低于对照组，差异有统计学意义（P < 0.05）；两组不良反应发生率比较，差异无统计学意义（P > 0.05）。 结论 美托洛尔联合左西孟旦能够改善CHF患者血清学指标，延缓心肌纤维化进展，安全可靠。 |
| 英文摘要: |
| [Abstract] Objective To investigate the effect of metoprolol combined with levosimendan in patients with chronic heart failure (CHF). Methods A total of 78 CHF patients treated in Lianjiang People’s Hospital in Guangdong Province from September 2019 to September 2020 were divided into two groups by random table number method, with 39 cases in each group. The control group was treated with metoprolol while the observation group was treated with levosimendan in addition to metoprolol for 14 days. The clinical efficacy, serological indexes, levels of myocardial fibrosis markers and adverse reactions were compared between the two groups. Results The total effective rate of the observation group (94.87%) was higher than that of the control group (76.92%), with statistically significant difference (P < 0.05). Before treatment, there were no statistically significant differences in cardiac troponin-T (cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), matrix metalloproteinase-9 (MMP-9), hyaluronic acid (HA), laminin (LN), connective tissue growth factor (CTGF) and procollagen typeⅢ amino terminal propeptide (PⅢNP) between the two groups (P > 0.05). After treatment, cTnT, NT-proBNP, MMP-9, HA, LN, CTGF and PⅢNP in the observation group were lower than those in the control group, with statistically significant differences (P < 0.05). There were no statistically significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Metoprolol combined with levosimendan can improve serological indexes and delay the progress of myocardial fibrosis in CHF patients, which is safe and reliable. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
.jpg)